| Literature DB >> 30697211 |
Zhenyu Wu1,2,3, Lingling Wang1,2,3, Jiaying Li1,2,3, Lifu Wang1,2,3, Zhongdao Wu1,2,3, Xi Sun1,2,3.
Abstract
Extracellular vesicles (EVs) are small membrane-surrounded structures released by different kinds of cells (normal, diseased, and transformed cells) in vivo and in vitro that contain large amounts of important substances (such as lipids, proteins, metabolites, DNA, RNA, and non-coding RNA (ncRNA), including miRNA, lncRNA, tRNA, rRNA, snoRNA, and scaRNA) in an evolutionarily conserved manner. EVs, including exosomes, play a role in the transmission of information, and substances between cells that is increasingly being recognized as important. In some infectious diseases such as parasitic diseases, EVs have emerged as a ubiquitous mechanism for mediating communication during host-parasite interactions. EVs can enable multiple modes to transfer virulence factors and effector molecules from parasites to hosts, thereby regulating host gene expression, and immune responses and, consequently, mediating the pathogenic process, which has made us rethink our understanding of the host-parasite interface. Thus, here, we review the present findings regarding EVs (especially exosomes) and recognize the role of EVs in host-parasite interactions. We hope that a better understanding of the mechanisms of parasite-derived EVs may provide new insights for further diagnostic biomarker, vaccine, and therapeutic development.Entities:
Keywords: exosome; extracellular vesicle; intercellular communication; parasite; parasite-host interaction
Mesh:
Substances:
Year: 2019 PMID: 30697211 PMCID: PMC6340962 DOI: 10.3389/fimmu.2018.03066
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Comparison and classification of EVs according to their mechanism of generation.
| Origin | Interior budding of the endosomal membrane to form large MVBs | Extracellular membrane yielding particles | Large-scale plasma membrane blebbing, released during apoptotic cell death ( | Larger size EV population from highly migratory cancer cells ( |
| Size | 30–150 nm | 100–1,000 nm | 1,000–5,000 nm | 1–10 μm |
| Specific markers | CD63, CD9, Alix HSP70, TSG101, | Annexin V, flotillin-2, CD40, integrin, metalloproteinase | Annexin V, DNA histone | Cav-1 |
| Separation method | Ultracentrifugation, gradient ultracentrifugation, precipitation solution, size exclusion chromatography (SEC) column purification, and microfluidic chip | Ultracentrifugation | No standardized approach | No standardized approach |
Essential information on various exosomes and exosomal molecules in different parasitic diseases.
| Malaria | Exosome-like vesicle | iRBC | Promote malaria transmission and parasite survival | Intercellular communication via gene delivery | Target of malaria therapeutics | ( | |
| Exosome | Infected reticulocyte | Induce reticulocytosis and a protective immune response | Antigen presentation by exosomes with parasite proteins | Malaria vaccine | ( | ||
| Exosome | iRBC | Inhibit angiogenesis and tumor growth | miRNAs in exosomes inhibit VEGFR2 expression in endothelial cells | Anticancer drug | ( | ||
| Leishmaniasis | Exosome | Parasite | Inhibit the macrophage immune response | Induce macrophages to secrete IL-8 rather than TNF-α | Unknown | ( | |
| Exosome | Parasite | Inhibit the immune responses of monocytes and monocyte-derived DCs | Facilitate IL-10 production and dampen TNF-α activation to inhibit the monocyte immune response to IFN-γ; reduce monocyte-derived DC production of inflammatory cytokines such as TNF-α, IL-10 and IL-12p70 | Vaccine adjuvant for leishmaniasis | ( | ||
| CPN10 | Parasite | Inhibit parasite survival but simultaneously dampen the macrophage immune response | Inhibit | Unknown | ( | ||
| Exosome | Infected macrophages | Modulate the host immune response and promote | Activate signal molecules and immune-related DNA | Unknown | ( | ||
| EF-1α | Parasite | Modulate the host immune response and promote | Activate PTPs, modulate IFN-γ signaling and inhibit macrophage reactions, including the production of TNF-α and NO | Unknown | ( | ||
| GP63* | Parasite | Immune modulation, exacerbation of the | Regulate PTPs and TFs in macrophages; inhibit IL-1β production via inhibition of the NLRP3 inflammasome; cleave Dicer1 and reduce miRNA-122 production and serum cholesterol; modulate | Potential therapeutic target | ( | ||
| LmPRL-1 | Parasite | Promote parasite survival in the host and induce protective immunity | Unknown | Unknown | ( | ||
| LieIF | Parasite | Inhibit | Promote NO and ROS production with or without activation of MIP-1a and TNF-α | Potential therapeutic molecule | ( | ||
| Toxoplasmosis | Exosome | Infected DCs | Induce protective immunity against | Prompt the proliferation of splenocytes with the enrichment of Th1 cytokines such as IL-2 and IFN-γ and reduced expression of Th2 cytokines such as IL-5 and IL-10 | Vaccine preparation | ( | |
| Exosome | Infected SRDCs | Induce protective immunity against | Induce a strong cellular response and humoral response, including the increased production of serum antibodies and IgA antibodies in the intestinal tract | Vaccine preparation | ( | ||
| Exosome | Infected macrophages | Induce protective immunity against | Exosomes contain PAMPs as a crucial mechanism for immune surveillance in a TLR- and MyD88-dependent manner | Vaccine preparation | ( | ||
| Exosome-like vesicle | Infected human foreskin fibroblasts | Most likely mediating neurologic effects in the | The exosome is full of mRNA, including thymosin beta 4, eukaryotic translation EF-1α, Rab-13 and LLP homolog, which were previously described to mediate neurologic activity | Unknown | ( | ||
| Exosome | Infected cells | L6 cells present alterations in the cell cycle and cell proliferation and retention at the S or G2/M cell phase | 11 miRNAs in exosomes were supposed to regulate the expression of host cell genes | Unknown | ( | ||
| Exosome | Parasite | Induce protective immunity against | Promote macrophage activation with increased production of IFN-γ, IL-12 and TNF-α; moreover, both humoral and cellular immune responses are stimulated in this process | Vaccine preparation | ( | ||
| Trichomoniasis | Exosome | Parasite | Facilitate | Promote pathogen adherence to epithelial cells; inhibit IL-8 secretion by ectocervical cells and neutrophil migration to the infection site | Potential use in trichomoniasis diagnosis and treatment | ( | |
| Exosome-like vesicle | Parasite | Modulate the host immune response and dampen the inflammatory reaction | Promote IL-10 production and inhibit the expression of immune cytokines such as IL-6, IL-13 and IL-17 | Unknown | ( | ||
| Exosome | Parasite | Play an important role in pathogenic processes and parasite nutrient supply | Mediate the release of most excreted/secreted proteins | Unknown | ( | ||
| Exosome | Parasite | Modulate | Keep pathogens away from injured cells and inappropriate environments | Unknown | ( | ||
| Exosome | Parasite | Modulate rRNA, snoRNA and mRNA processing and quality control | Unknown | Unknown | ( | ||
| Exosome | Parasite | Promote the transformation of | Exosome-contained tsRNAs can be passed on to other pathogen and host cells | Unknown | ( | ||
| Schistosomiasis | Exosome-like vesicle | Parasite | Mediate parasite-host communications and activate the host immune response | Promote M1 macrophage polarization with increased production of pro-inflammatory factors | Potential use of diagnostic markers, new vaccines, and therapies for schistosomiasis | ( | |
| Exosome-like vesicle | Parasite | Deliver miRNA to mammalian cells | Mediate parasite-host interactions | Unknown | ( | ||
| Exosome | Attenuate the severity and repress the progression of IBD | Reduce the production of pro-inflammatory cytokines and promote the production of anti-inflammatory cytokines via an unknown mechanism | Immunosuppressive drug | ( | |||
| Exosome | Parasite | Play important roles in host-parasite interactions | Not clear | Vaccines and therapeutics | ( | ||
| EVs | Sera of infected patients | New tool for diagnosing schistosomiasis | The 2 highest expressed miRNAs in the EVs has the highest sensitivity and specificity. | Diagnosis method | ( | ||
| Lymphatic filariasis | Exosome-like vesicle | Parasite | Plays an important role in early infection; regulate the host immune response | Deliver proteins and small RNA species; M1 macrophage polarization | New targets for disease intervention and diagnosis | ( | |
| Fascioliasis | Exosome-like vesicle | Parasite | Parasite-host communications | Exosome-like vesicles are internalized by intestinal cells | Unknown | ( | |
| Rodent intestinal infection | Exosome | Parasite | Inhibit a type 2 innate response and eosinophilia activation, subsequently repressing the host immune response; 9- to 62-fold increase in plasmalogen content and a relative lack of sphingomyelin and cholesterol in | miRNA and Y RNA in exosomes suppress the expression of genes related to inflammatory reactions such as dampening the activation of IL-33 and DUSP1; increase membrane rigidity and stability | Potential use of immunomodulatory treatment | ( | |
| Cystic echinococcosis | Exosome | Parasite | Have an important effect on macrophages and the interplay between parasites and hosts | Exosomes have highly immunogenic and tolerogenic antigens and peptidases. | Unknown | ( | |
| Exosomes can reduce the production of NO but do not affect IL-10 | |||||||
| Parasitic gastroenteritis | Exosome-like vesicle | Parasite | Affect host immunity | Proteins in exosome-like vesicles can be bound by IgA and IgG | Potentially key for vaccine development and production | ( |
Figure 1Three EV production modes associated with parasitic infection.